The Technical Analyst
Stoke Therapeutics Inc [STOK]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Stoke Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.26% $11.69
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 606.24 mill |
| EPS: | -2.38 |
| P/E: | -4.91 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 51.86 mill |
| Avg Daily Volume: | 1.207 mill |
| RATING 2024-04-25 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.91 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.84x |
| Company: PE -4.91 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$4.37 (-62.66%) $-7.32 |
| Date: 2024-04-25 |
| Expected Trading Range (DAY) |
|---|
|
$ 10.23 - 13.15 ( +/- 12.46%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-17 | Skorpios Trust | Sell | 3 600 000 | Common Stock |
| 2024-04-01 | Ticho Barry | Sell | 442 | Stock Option (Right to Buy) |
| 2024-04-01 | Ticho Barry | Buy | 442 | Common Stock |
| 2024-04-01 | Ticho Barry | Sell | 9 426 | Common Stock |
| 2024-04-01 | Nash Huw M. | Sell | 50 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| -65.50 |
| Last 99 transactions |
| Buy: 2 052 338 | Sell: 5 167 636 |
Forecast:
16:00 - $11.69
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $11.69
Forecast 2: 16:00 - $11.69
Forecast 3: 16:00 - $11.69
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $11.69 (0.26% ) |
| Volume | 0.508 mill |
| Avg. Vol. | 1.207 mill |
| % of Avg. Vol | 42.07 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For STOK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 14 - 15:52 | buy | $5.36 | N/A | Active |
|---|
STOK
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Latest Press Releases
2024-04-17 08:00:00 - Press Release
Stoke Therapeutics Appoints Jason Hoitt As Chief Commercial Officer
Bedford, mass.--(business wire)--stoke therapeutics, inc. (nasdaq: stok), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with rna-based medicines, today announced the appointment of jason hoitt as chief commercial officer. mr. hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. as chief commercial officer and a member of stoke's leadership.
2024-04-04 16:30:00 - Press Release
Stoke Therapeutics To Present At The 23rd Annual Needham Virtual Healthcare Conference
Bedford, mass.--(business wire)--stoke therapeutics, inc. (nasdaq: stok), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with rna-based medicines, today announced that management will present at the 23rd annual needham virtual healthcare conference on wednesday, april 10, 2024, at 10:15 a.m. et. a live webcast of the presentation, which will be conducted in fireside chat format, will be available on the investors &.
2024-03-27 23:40:00 - Press Release
Stoke Therapeutics Announces Pricing Of Upsized $125 Million Public Offering
Bedford, mass.--(business wire)--stoke therapeutics, inc. (nasdaq: stok), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with rna-based medicines, today announced the pricing of its upsized underwritten public offering of 5,555,557 shares of its common stock at a price to the public of $13.50 per share and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 3,703,7.
2024-03-26 16:07:00 - Press Release
Stoke Therapeutics Announces Proposed Public Offering
Bedford, mass.--(business wire)--stoke therapeutics, inc. (nasdaq: stok), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with rna-based medicines, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75 million of shares of its common stock. in addition, stoke intends to grant the underwriters a 30-day option to purchase up to an ad.
2024-03-25 16:01:00 - Press Release
Stoke Therapeutics Announces Landmark New Data That Support The Potential For Stk-001 To Be The First Disease-modifying Medicine For The Treatment Of Patients With Dravet Syndrome
Bedford, mass.--(business wire)--stoke therapeutics, inc. (nasdaq: stok), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with rna-based medicines, today announced landmark new data from two open-label phase 1/2a studies and two open-label extension (ole) studies of children and adolescents ages 2 to 18 with dravet syndrome who were treated with stk-001. data from these studies showed clinically meaningful effects, inclu.
Latest News
2024-04-04 16:30:00 - Business Wire
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 10:15 a.m. ET. A live webcast of the presentation, which will be conducted in fireside chat format, will be available on the Investors &.
2024-03-27 09:51:10 - Zacks Investment Research
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.
2024-03-25 18:10:25 - Zacks Investment Research
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.65 per share a year ago.
2024-02-29 09:51:13 - Zacks Investment Research
Why Earnings Season Could Be Great for Stoke Therapeutics (STOK)
Stoke Therapeutics (STOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
2024-02-26 11:01:09 - Zacks Investment Research
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?
Stoke Therapeutics, Inc. (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-02-25 13:37:41 - InvestorPlace
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.
2024-02-19 14:31:09 - InvestorPlace
Triple Threat: 3 Stocks to Buy for 3X Upside Potential
You want speculative stocks with upside potential up to 3X returns? I'm going to give them to you.
2024-02-15 10:56:05 - Zacks Investment Research
Does Stoke Therapeutics, Inc. (STOK) Have the Potential to Rally 284.14% as Wall Street Analysts Expect?
The mean of analysts' price targets for Stoke Therapeutics, Inc. (STOK) points to a 284.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-02-15 08:01:09 - Zacks Investment Research
Stoke Therapeutics, Inc. (STOK) Stock Jumps 25.5%: Will It Continue to Soar?
Stoke Therapeutics, Inc. (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2024-02-14 06:50:12 - Zacks Investment Research
New Strong Buy Stocks for February 14th
GLTO, LUMN, MORF, SFST and STOK have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.